Bright Minds Biosciences (DRUG) Competitors $63.14 -3.26 (-4.91%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$64.63 +1.49 (+2.36%) As of 10/17/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRUG vs. GPCR, BHVN, STOK, ABCL, IMCR, VCEL, JANX, EWTX, RCUS, and HRMYShould you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include Structure Therapeutics (GPCR), Biohaven (BHVN), Stoke Therapeutics (STOK), AbCellera Biologics (ABCL), Immunocore (IMCR), Vericel (VCEL), Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), Arcus Biosciences (RCUS), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. Bright Minds Biosciences vs. Its Competitors Structure Therapeutics Biohaven Stoke Therapeutics AbCellera Biologics Immunocore Vericel Janux Therapeutics Edgewise Therapeutics Arcus Biosciences Harmony Biosciences Structure Therapeutics (NASDAQ:GPCR) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk. Do analysts rate GPCR or DRUG? Structure Therapeutics currently has a consensus price target of $68.67, suggesting a potential upside of 150.79%. Bright Minds Biosciences has a consensus price target of $81.00, suggesting a potential upside of 28.29%. Given Structure Therapeutics' higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Bright Minds Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Structure Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20 Which has more risk and volatility, GPCR or DRUG? Structure Therapeutics has a beta of -1.65, suggesting that its share price is 265% less volatile than the S&P 500. Comparatively, Bright Minds Biosciences has a beta of -6.17, suggesting that its share price is 717% less volatile than the S&P 500. Which has stronger earnings and valuation, GPCR or DRUG? Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Structure Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStructure TherapeuticsN/AN/A-$122.53M-$1.05-26.08Bright Minds BiosciencesN/AN/A-$2.06M-$0.93-67.89 Is GPCR or DRUG more profitable? Bright Minds Biosciences' return on equity of -20.96% beat Structure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Structure TherapeuticsN/A -21.31% -20.34% Bright Minds Biosciences N/A -20.96%-20.66% Does the media prefer GPCR or DRUG? In the previous week, Structure Therapeutics had 2 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 4 mentions for Structure Therapeutics and 2 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.29 beat Structure Therapeutics' score of 0.88 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bright Minds Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in GPCR or DRUG? 91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 5.6% of Structure Therapeutics shares are owned by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryBright Minds Biosciences beats Structure Therapeutics on 8 of the 14 factors compared between the two stocks. Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRUG vs. The Competition Export to ExcelMetricBright Minds BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$444.76M$3.45B$6.15B$10.56BDividend YieldN/A2.27%5.72%4.84%P/E Ratio-67.898.2364.2322.90Price / SalesN/A486.95612.78132.51Price / CashN/A45.2825.8230.35Price / Book68.6310.3812.226.58Net Income-$2.06M-$52.81M$3.33B$276.84M7 Day Performance-0.24%2.31%1.17%1.93%1 Month Performance18.51%12.59%6.85%2.19%1 Year Performance33.74%11.18%58.93%34.62% Bright Minds Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRUGBright Minds Biosciences3.2063 of 5 stars$63.14-4.9%$81.00+28.3%+33.7%$444.76MN/A-67.89N/APositive NewsGPCRStructure Therapeutics3.2826 of 5 stars$30.19+0.4%$68.67+127.4%-30.7%$1.73BN/A-28.75136News CoverageBHVNBiohaven3.4683 of 5 stars$15.29-3.3%$48.85+219.6%-69.8%$1.67BN/A-2.00239STOKStoke Therapeutics3.5362 of 5 stars$30.34+0.5%$29.00-4.4%+157.9%$1.65B$36.56M35.69100ABCLAbCellera Biologics2.4922 of 5 stars$5.67+2.5%$8.00+41.1%+94.8%$1.65B$28.83M-10.31500IMCRImmunocore1.9677 of 5 stars$32.35-0.2%$56.89+75.9%-2.4%$1.63B$310.20M-80.88320VCELVericel3.3348 of 5 stars$33.49+5.1%$60.40+80.4%-15.2%$1.61B$237.22M279.11300News CoverageAnalyst UpgradeAnalyst RevisionJANXJanux Therapeutics2.2225 of 5 stars$26.29-0.8%$78.31+197.9%-46.5%$1.59B$10.59M-14.6130News CoverageEWTXEdgewise Therapeutics3.1341 of 5 stars$14.71-2.6%$38.83+164.0%-57.7%$1.59BN/A-9.4960RCUSArcus Biosciences2.4046 of 5 stars$16.64+14.0%$26.78+61.0%-10.6%$1.55B$258M-5.25500Gap UpHRMYHarmony Biosciences4.7602 of 5 stars$26.36-0.7%$46.11+74.9%-26.9%$1.53B$714.73M8.50200Analyst Forecast Related Companies and Tools Related Companies Structure Therapeutics Competitors Biohaven Competitors Stoke Therapeutics Competitors AbCellera Biologics Competitors Immunocore Competitors Vericel Competitors Janux Therapeutics Competitors Edgewise Therapeutics Competitors Arcus Biosciences Competitors Harmony Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRUG) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
